In Vitro Gene Transfection with Surface-Modified Gelatin Nanoparticles

Zwiorek, Klaus; Kloeckner, Julia; Wagner, Ernst; Coester, Conrad

doi:10.1109/icmens.2004.1508915

Cited by 7 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 In particular, gelatin nanoparticles have the potential to protein drug delivery system in terms of simple preparation, 3,4 biocompatibility and biodegradability because the gelatin derived from bovine or porcine widely used in pharmaceutical industry as capsule materials and stabilizers. [5][6][7] However, animal origin gelatin might cause transmissible mad cow disease and anaphylaxis.…”

Section: Introductionmentioning

confidence: 99%

Preparation and cytotoxicity comparison of type a gelatin nanoparticles with recombinant human gelatin nanoparticles

Won

Kim

2009

Macromol. Res.

View full text Add to dashboard Cite

Gelatin nanoparticles derived from bovine or porcine have been developed as various types of drug delivery system, and they need to be cross-linked to maintain their physicochemical properties in aqueous environments. Although gelatin is a widely used material in pharmaceutical industries, the safety issue of animal-origin gelatins, such as transmissible mad cow disease and anaphylaxis, remains to be solved. The purpose of this study was to prepare type A gelatin (GA) nanoparticles by modified, two-step, desolvation method and compare the toxicity of the resulting GA nanoparticles with recombinant human gelatin (rHG) nanoparticles. The GA nanoparticles were characterized, and drug loading and release pattern were measured. FITC-BSA, a model protein, was efficiently loaded in the nanoparticles and then released in a biphasic and sustained release pattern without an initial burst. In particular, the cell viability of the GA nanoparticles was less than that of the rHG nanoparticles. This finding suggests that rHG nanoparticles should be considered as an alternative to animal-origin gelatin nanoparticles in order to minimize the safety problems.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and cytotoxicity comparison of type a gelatin nanoparticles with recombinant human gelatin nanoparticles

Won

Kim

2009

Macromol. Res.

View full text Add to dashboard Cite

show abstract

“…Additionally, there is only a limited possibility of modifying the release from PLGA matrices. Besides PLGA, many other types of biodegradable polymers are being investigated to design drug-containing nanoparticles, like, e.g., poly(cyanoacrylates) (PCA), chitosan, gelatin, sodium alginate. , …”

Section: Introductionmentioning

confidence: 99%

Protein Release from Biodegradable Dextran Nanogels

et al. 2007

View full text Add to dashboard Cite

The use of drugs with intracellular targets will strongly depend on the availability of delivery systems that are able to deliver them to specific intracellular sites at an optimal rate. Biodegradable dextran nanogels were prepared using liposomes as a nanoscaled reactor.1,2 These nanogels were obtained by UV polymerization of dextran hydroxyethylmethacrylate (dex-HEMA) containing 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC) liposomes. We found the encapsulation efficiency of bovine serum albumin (BSA) and lysozyme in the dextran nanogels to be about 50%. Specifically, the release of BSA and lysozyme from the dextran nanogels was clearly governed by the cross-link density of the tiny gels. Depending on the size of the encapsulated protein, the cross-link density of the dextran network, and the presence or absence of a lipid coating, proteins were released from the nanogels over days to weeks. Interestingly, when sufficiently diluted, dextran nanogels did not aggregate in human serum, which is of major importance when one considers intravenous administration of such nanogels. Also, reconstitution of lyophilized dextran nanogels seemed perfectly possible, which is also an important finding since dextran nanogels will have to be stored in dry form. Because dextran nanogels can be taken up by cells, they are promising materials for controlled intracellular release of proteins.

show abstract

“…[152] In addition, covalent functionalisation of biopolymers with positively charged amino acids,p eptides,o rs mall molecules (Figure 6) can be used for charge tuning.F or example, arginine,histidine,and lysine were employed to functionalise dextran, [153][154][155] chitosan, [51] alginate, [59] human serum albumin (HSA), [78,156] HA, [116] and chondroitin sulfate. [157] Other small moieties used for biopolymer modification include quaternary amines, [56,73,[158][159][160] spermine, [63,161,162] piperazine, [163] cystamine, [69] and succinyl tetraethylene pentamine. [164] Moreover,the polymer backbone itself can be chemically modified to modulate its intrinsic charge.C hitosan, which is positively charged only at acidic pH, can be trimethylated at its primary amines resulting in ap ositive charge over ab roader pH range.…”

Section: Polysaccharidesmentioning

confidence: 99%

“…For example, arginine, histidine, and lysine were employed to functionalise dextran, [153–155] chitosan, [51] alginate, [59] human serum albumin (HSA), [78, 156] HA, [116] and chondroitin sulfate [157] . Other small moieties used for biopolymer modification include quaternary amines, [56, 73, 158–160] spermine, [63, 161, 162] piperazine, [163] cystamine, [69] and succinyl tetraethylene pentamine [164] …”

Section: Biopolymers As Dna Vaccine Carriersmentioning

confidence: 99%

Biopolymer‐based Carriers for DNA Vaccine Design

et al. 2021

View full text Add to dashboard Cite

She studied chemistry at the University of Zagreb, and completed her PhD at the University of Strathclyde,G lasgow,w orking on DNA detection by advanced spectroscopies, such as SERRS. After postdoc research on DNA nanostructuring and artificial enzyme design at the University of Dortmund,s he was agroup leader at Karlsruhe Institute of Technology before joining Cambridge. Her research focuses on nanostructured biomaterials for use in photocatalysis and targeted drug delivery.

show abstract

In Vitro Gene Transfection with Surface-Modified Gelatin Nanoparticles

Cited by 7 publications

References 10 publications

Preparation and cytotoxicity comparison of type a gelatin nanoparticles with recombinant human gelatin nanoparticles

Preparation and cytotoxicity comparison of type a gelatin nanoparticles with recombinant human gelatin nanoparticles

Protein Release from Biodegradable Dextran Nanogels

Biopolymer‐based Carriers for DNA Vaccine Design

Contact Info

Product

Resources

About